Retatrutide — Next-Generation Triple Agonist in Ukraine
The world's first triple GLP-1 + GIP + glucagon agonist by Eli Lilly. Phase 2 clinical trials showed weight loss of up to -24.2% over 48 weeks. Choose your ALLUVI or SYNEDICA dose.
Price from
15,000 UAH
Choose Your Retatrutide Dose
7
Retatrutide Program
Retatrutide
Buy retatrutide from 1.5 to 12 mg · step 0.5 mgBuy retatrutide (Retatrutide) dose from 1.5 to 12 mg in 0.5 mg steps. Dose selection with specialist, delivery across Ukraine.
Retatrutide 12 mg (PEN PEPTIDE)
Next-generation triple agonist · 12 mg · Pre-Mixed Stabilized Pen · PEN PEPTIDE
Retatrutide 12 mg from PEN PEPTIDE — stabilized pen with triple GLP-1/GIP/glucagon agonist. 120 units of 100 mcg each. Optimal for dose escalation phase. MSSPT technology.
Retatrutide 40 mg (ALLUVI)
Next-generation triple agonist · 40 mg pen · ALLUVI Healthcare
Retatrutide 40 mg by ALLUVI Healthcare — injection pen with triple agonist GLP-1/GIP/glucagon. 4 full doses of 10 mg (40 mg total), 12 needles included, dosing instructions.
Retatrutide 40 mg (SYNEDICA)
Next-generation triple agonist · 40 mg per pen · Synedica Laboratories · Made in Germany
Retatrutide 40 mg from Synedica Laboratories (Germany) — injection pen with triple agonist GLP-1/GIP/glucagon. 4 full doses of 10 mg each (40 mg total), 12 needles 32g 4mm included, instruction manual. Once weekly. Kit lasts approximately 12 weeks on average.
Retatrutide 6 mg (PEN PEPTIDE)
Next-generation triple agonist · 6 mg · Pre-Mixed Stabilized Pen · PEN PEPTIDE
Retatrutide 6 mg from PEN PEPTIDE — stabilized pen injector with triple agonist GLP-1/GIP/glucagon. 120 units of 50 mcg each. Starting dose for course initiation. MSSPT technology — stable formula.
Retatrutide 20 mg (PEN PEPTIDE)
Next-generation triple agonist · 20 mg · Pre-Mixed Stabilized Pen · PEN PEPTIDE
Retatrutide 20 mg from PEN PEPTIDE — stabilized pen with triple GLP-1/GIP/glucagon agonist. 200 units of 100 mcg each. Optimal for maintenance dosing. MSSPT technology.
Retatrutide 40 mg (PEN PEPTIDE)
Next-generation triple agonist · 40 mg · Pre-Mixed Stabilized Pen · PEN PEPTIDE
Retatrutide 40 mg by PEN PEPTIDE — stabilized pen injector with triple GLP-1/GIP/glucagon agonist. 200 units of 200 mcg each. Maximum volume for extended treatment course. MSSPT technology.
Buy Retatrutide in Ukraine
Retatrutide is an innovative triple agonist of GLP-1, GIP, and glucagon receptors developed by Eli Lilly. Unlike tirzepatide (a dual agonist), retatrutide activates three receptors simultaneously, providing the most powerful weight loss effect among all existing products.
Phase 2 clinical trial results showed unprecedented weight loss of up to -24.2% over 48 weeks — the highest result among all investigated GLP-1 products. Retatrutide is currently undergoing large-scale Phase 3 trials (the TRIUMPH program).
In Ukraine, retatrutide is available under the brands ALLUVI (injector pens) and SYNEDICA (injector pens) with 2-8°C cold chain delivery nationwide.
DOZA provides a full support cycle — from dose selection with a specialist to results monitoring. Every delivery comes in a certified thermal box with a temperature sensor.
Starting from 15,000 UAH per injector pen. Free delivery and specialist consultation.
Why Choose Retatrutide at DOZA
Triple Mechanism of Action
The only product that simultaneously activates GLP-1, GIP, and glucagon receptors — maximum weight loss efficacy
Up to -24.2% Weight Loss
The highest weight loss result among all GLP-1 products according to Phase 2 clinical trial data
Cold Chain Delivery 2-8°C
Certified thermal box with temperature sensor — guaranteed product quality preservation
24/7 Support
Personal specialist from dose selection to reaching your target weight
ALLUVI & SYNEDICA Brands
Injector pens with precision dosing for convenient self-administration
TRIUMPH Program
Currently undergoing large-scale Phase 3 trials — confirming efficacy and safety
Over 2,147 clients trust DOZA with their weight loss program Learn more about Retatrutide · All DOZA programs
How to Order Retatrutide
Consultation
Free consultation with a DOZA specialist — dose and program selection
Order
Place your order via Telegram with 2-8°C cold chain delivery
Support
Personal progress monitoring and dose adjustment throughout your entire program
Which Retatrutide Dose Is Right for You?
Take a short quiz — a DOZA specialist will select the optimal ALLUVI or SYNEDICA dose for you
Frequently Asked Questions About Retatrutide
Retatrutide is an innovative triple agonist of GLP-1, GIP, and glucagon receptors developed by Eli Lilly. It is the world's first product that simultaneously activates three key receptors for weight management. Phase 2 clinical trials showed weight loss of up to -24.2% over 48 weeks.
Anastasia Shapoval
Metabolic Programs and Weight Control Specialist
Ready to Start with Retatrutide?
Free consultation with a DOZA specialist — we'll select the optimal ALLUVI or SYNEDICA dose for your weight loss program
Get a consultationMessage on Telegram
You May Also Be Interested In
Mounjaro
Dual GLP-1 + GIP agonist by Eli Lilly. Up to -22.5% weight loss over 72 weeks. The gold standard of GLP-1 therapy.
Ozempic
GLP-1 agonist by Novo Nordisk. A proven product with the broadest evidence base for weight loss.
Client Results
Real results and reviews from DOZA clients — before/after photos, video reviews, success stories.
Weight Loss Program
Comprehensive DOZA weight loss program with personal 24/7 specialist support.
DOZA Peptides
Peptide catalog for health, energy, and recovery — MOTS-c, BPC-157, Ipamorelin, and more.
⚠️ Retatrutide is an investigational product currently undergoing Phase 3 clinical trials. Results may vary. Consult a specialist before starting the program. Retatrutide is developed by Eli Lilly and Company. ALLUVI and SYNEDICA are trade names of retatrutide injector pens.